Imugene doses first azer-cel combination patient
Imugene (ASX:IMU) announced a milestone in its ongoing Phase 1b basket study of azer-cel.
Todas as matérias desta categoria, das mais recentes às mais antigas.
Imugene (ASX:IMU) announced a milestone in its ongoing Phase 1b basket study of azer-cel.
Acrux (ASX:ACR) finalised an amendment to its licensing agreement with Gedeon Richter for the transdermal estradiol spray, Lenzetto.
Australian Clinical Labs (ASX:ACL) appointed Greg Horan as its new Group CEO and executive director.
Biome Australia (ASX:BIO) has launched its multi-centre, international clinical trial for BMB18.
Noxopharm (ASX:NOX) shares surge on data showing its proprietary Sofra platform can amplify immune cells to actively fight cancer.
Osteopore (ASX:OSX) secured a major regulatory breakthrough, obtaining approval from the Hainan Medical Products Administration.
Ryman Healthcare (ASX:RYM) achieved its first positive free cash flow in over a decade, reaching NZ$188 million.
Cancer diagnostics company Pacific Edge (ASX:PEB) reported its audited financial results for the 2026 financial year.
HITIQ (ASX:HIQ) executed a non-dilutive grant agreement with the Victorian Government to heavily bolster its domestic operations.
Imugene (ASX:IMU) has released Phase 1b data for its innovative allogeneic CD19 CAR T-cell therapy, azer-cel.
PainChek (ASX:PCK) entered into binding agreements to raise $5.5 million through the issuance of unsecured convertible notes.
Bio-Gene Technology (ASX:BGT) announced an expansion of its vector control programmes into Asia.
Tem um segundo para um cookie? 🍪Os cookies essenciais mantêm a Grafa funcionando bem. Alguns opcionais nos ajudam a ver o que está funcionando para melhorarmos. Você tem o controle — pode mudar de ideia quando quiser. Política de cookies · Política de privacidade